Gastric Cancer – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Gastric Cancer – Pipeline Review, H1 2017’, provides an overview of the Gastric Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastric Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Gastric Cancer

The report reviews pipeline therapeutics for Gastric Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Gastric Cancer therapeutics and enlists all their major and minor projects

The report assesses Gastric Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Gastric Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Gastric Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

AB Science SA

AbbVie Inc

AbGenomics International Inc

Abion Inc

Adaptimmune Therapeutics Plc

ADC Therapeutics Sarl

Aduro BioTech Inc

Advaxis Inc

Advenchen Laboratories LLC

Agenus Inc

Almac Discovery Ltd

Alteogen Inc

Ambrx Inc

amcure GmbH

Amgen Inc

ANP Technologies Inc

Antikor Biopharma Ltd

arGEN-X BV

Array BioPharma Inc

Asana BioSciences LLC

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

AstraZeneca Plc

Athenex Inc

Basilea Pharmaceutica Ltd

Bayer AG

BeiGene Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Betta Pharmaceuticals Co Ltd

Bionovis SA

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Camel-IDS NV

Cancer Prevention Pharmaceuticals Inc

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celltrion Inc

Celon Pharma SA

Chipscreen Biosciences Ltd

Curaxys SL

Cytori Therapeutics Inc

Daiichi Sankyo Company Ltd

Debiopharm International SA

Deciphera Pharmaceuticals LLC

Dr. Reddy's Laboratories Ltd

Eli Lilly and Company

EOS Biosciences Inc

Erytech Pharma SA

Esperance Pharmaceuticals Inc

Exelixis Inc

F-star Biotechnology Ltd

F. Hoffmann-La Roche Ltd

Five Prime Therapeutics Inc

Frost Biologic Inc

Galena Biopharma Inc

Genelux Corp

Genentech Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

GlycoNex Inc

Glycotope GmbH

Green Cross Corp

Halozyme Therapeutics Inc

Hanmi Pharmaceuticals Co Ltd

Horizon Pharma Plc

Hutchison China MediTech Ltd

Ignyta Inc

Ildong Pharmaceutical Co Ltd

Immunomedics Inc

Incyte Corp

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

Insys Therapeutics Inc

Intezyne Technologies Inc

Ipsen SA

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

KaloBios Pharmaceuticals Inc

Kuhnil Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

LATITUDE Pharmaceuticals Inc

LegoChem Biosciences Inc

Les Laboratoires Servier SAS

MacroGenics Inc

MaxiVAX SA

Mebiopharm Co Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Mersana Therapeutics Inc

Merus NV

Mirati Therapeutics Inc

Molecular Partners AG

Molecular Targeting Technologies Inc

MolMed SpA

NanoCarrier Co Ltd

Novartis AG

Novogen Ltd

OBI Pharma Inc

Oncobiologics Inc

Oncolys BioPharma Inc

OncoMed Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Panacea Biotec Ltd

Patrys Ltd

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Puma Biotechnology Inc

Redx Pharma Plc

Rexahn Pharmaceuticals Inc

Rgenix Inc

Rhizen Pharmaceuticals SA

Richter Gedeon Nyrt

Samumed LLC

Sanofi

Selecta Biosciences Inc

Sequella Inc

Shionogi & Co Ltd

Simcere Pharmaceutical Group

Sorrento Therapeutics Inc

Spectrum Pharmaceuticals Inc

Stelic Institute & Co Inc

Supratek Pharma Inc

SynCore Biotechnology Co Ltd

Synovo GmbH

Synthon Holdings BV

Taiho Pharmaceutical Co Ltd

Taiwan Liposome Company Ltd

Takis Srl

Tessa Therapeutics Pte Ltd

Transgene SA

United BioPharma Inc

Vaxon Biotech

Viracta Therapeutics Inc

XuanZhu Pharma Co Ltd

Zymeworks Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Gastric Cancer - Overview 9

Gastric Cancer - Therapeutics Development 10

Gastric Cancer - Therapeutics Assessment 40

Gastric Cancer - Companies Involved in Therapeutics Development 58

Gastric Cancer - Drug Profiles 131

Gastric Cancer - Dormant Projects 935

Gastric Cancer - Discontinued Products 943

Gastric Cancer - Product Development Milestones 946

Appendix 954

List of Tables

List of Tables

Number of Products under Development for Gastric Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Gastric Cancer – Pipeline by 3SBio Inc, H1 2017

Gastric Cancer – Pipeline by AB Science SA, H1 2017

Gastric Cancer – Pipeline by AbbVie Inc, H1 2017

Gastric Cancer – Pipeline by AbGenomics International Inc, H1 2017

Gastric Cancer – Pipeline by Abion Inc, H1 2017

Gastric Cancer – Pipeline by Adaptimmune Therapeutics Plc, H1 2017

Gastric Cancer – Pipeline by ADC Therapeutics Sarl, H1 2017

Gastric Cancer – Pipeline by Aduro BioTech Inc, H1 2017

Gastric Cancer – Pipeline by Advaxis Inc, H1 2017

Gastric Cancer – Pipeline by Advenchen Laboratories LLC, H1 2017

Gastric Cancer – Pipeline by Agenus Inc, H1 2017

Gastric Cancer – Pipeline by Almac Discovery Ltd, H1 2017

Gastric Cancer – Pipeline by Alteogen Inc, H1 2017

Gastric Cancer – Pipeline by Ambrx Inc, H1 2017

Gastric Cancer – Pipeline by amcure GmbH, H1 2017

Gastric Cancer – Pipeline by Amgen Inc, H1 2017

Gastric Cancer – Pipeline by ANP Technologies Inc, H1 2017

Gastric Cancer – Pipeline by Antikor Biopharma Ltd, H1 2017

Gastric Cancer – Pipeline by arGEN-X BV, H1 2017

Gastric Cancer – Pipeline by Array BioPharma Inc, H1 2017

Gastric Cancer – Pipeline by Asana BioSciences LLC, H1 2017

Gastric Cancer – Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017

Gastric Cancer – Pipeline by Astellas Pharma Inc, H1 2017

Gastric Cancer – Pipeline by AstraZeneca Plc, H1 2017

Gastric Cancer – Pipeline by Athenex Inc, H1 2017

Gastric Cancer – Pipeline by Basilea Pharmaceutica Ltd, H1 2017

Gastric Cancer – Pipeline by Bayer AG, H1 2017

Gastric Cancer – Pipeline by BeiGene Ltd, H1 2017

Gastric Cancer – Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2017

Gastric Cancer – Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017

Gastric Cancer – Pipeline by Bionovis SA, H1 2017

Gastric Cancer – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Gastric Cancer – Pipeline by Boston Biomedical Inc, H1 2017

Gastric Cancer – Pipeline by Bristol-Myers Squibb Company, H1 2017

Gastric Cancer – Pipeline by Camel-IDS NV, H1 2017

Gastric Cancer – Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017

Gastric Cancer – Pipeline by CBT Pharmaceuticals Inc, H1 2017

Gastric Cancer – Pipeline by Celgene Corp, H1 2017

Gastric Cancer – Pipeline by Celldex Therapeutics Inc, H1 2017

Gastric Cancer – Pipeline by Cellectar Biosciences Inc, H1 2017

Gastric Cancer – Pipeline by Celltrion Inc, H1 2017

Gastric Cancer – Pipeline by Celon Pharma SA, H1 2017

Gastric Cancer – Pipeline by Chipscreen Biosciences Ltd, H1 2017

Gastric Cancer – Pipeline by Curaxys SL, H1 2017

Gastric Cancer – Pipeline by Cytori Therapeutics Inc, H1 2017

Gastric Cancer – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Gastric Cancer – Pipeline by Debiopharm International SA, H1 2017

Gastric Cancer – Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Gastric Cancer – Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017

Gastric Cancer – Pipeline by Eli Lilly and Company, H1 2017

Gastric Cancer – Pipeline by EOS Biosciences Inc, H1 2017

Gastric Cancer – Pipeline by Erytech Pharma SA, H1 2017

Gastric Cancer – Pipeline by Esperance Pharmaceuticals Inc, H1 2017

Gastric Cancer – Pipeline by Exelixis Inc, H1 2017

Gastric Cancer – Pipeline by F-star Biotechnology Ltd, H1 2017

Gastric Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Gastric Cancer – Pipeline by Five Prime Therapeutics Inc, H1 2017

Gastric Cancer – Pipeline by Frost Biologic Inc, H1 2017

Gastric Cancer – Pipeline by Galena Biopharma Inc, H1 2017

Gastric Cancer – Pipeline by Genelux Corp, H1 2017

Gastric Cancer – Pipeline by Genentech Inc, H1 2017

Gastric Cancer – Pipeline by Gilead Sciences Inc, H1 2017

Gastric Cancer – Pipeline by GlaxoSmithKline Plc, H1 2017

Gastric Cancer – Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Gastric Cancer – Pipeline by GlycoNex Inc, H1 2017

Gastric Cancer – Pipeline by Glycotope GmbH, H1 2017

Gastric Cancer – Pipeline by Green Cross Corp, H1 2017

Gastric Cancer – Pipeline by Halozyme Therapeutics Inc, H1 2017

Gastric Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Gastric Cancer – Pipeline by Horizon Pharma Plc, H1 2017

Gastric Cancer – Pipeline by Hutchison China MediTech Ltd, H1 2017

Gastric Cancer – Pipeline by Ignyta Inc, H1 2017

Gastric Cancer – Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017

Gastric Cancer – Pipeline by Immunomedics Inc, H1 2017

Gastric Cancer – Pipeline by Incyte Corp, H1 2017

Gastric Cancer – Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Gastric Cancer – Pipeline by Inspyr Therapeutics Inc, H1 2017

Gastric Cancer – Pipeline by Insys Therapeutics Inc, H1 2017

Gastric Cancer – Pipeline by Intezyne Technologies Inc, H1 2017

Gastric Cancer – Pipeline by Ipsen SA, H1 2017

Gastric Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Gastric Cancer – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017

Gastric Cancer – Pipeline by Johnson & Johnson, H1 2017

Gastric Cancer – Pipeline by KaloBios Pharmaceuticals Inc, H1 2017

Gastric Cancer – Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017

Gastric Cancer – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Gastric Cancer – Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017

Gastric Cancer – Pipeline by LegoChem Biosciences Inc, H1 2017

Gastric Cancer – Pipeline by Les Laboratoires Servier SAS, H1 2017

Gastric Cancer – Pipeline by MacroGenics Inc, H1 2017

Gastric Cancer – Pipeline by MaxiVAX SA, H1 2017

Gastric Cancer – Pipeline by Mebiopharm Co Ltd, H1 2017

Gastric Cancer – Pipeline by MedImmune LLC, H1 2017

Gastric Cancer – Pipeline by Merck & Co Inc, H1 2017

Gastric Cancer – Pipeline by Merck KGaA, H1 2017

Gastric Cancer – Pipeline by Mersana Therapeutics Inc, H1 2017

Gastric Cancer – Pipeline by Merus NV, H1 2017

Gastric Cancer – Pipeline by Mirati Therapeutics Inc, H1 2017

Gastric Cancer – Pipeline by Molecular Partners AG, H1 2017

Gastric Cancer – Pipeline by Molecular Targeting Technologies Inc, H1 2017

Gastric Cancer – Pipeline by MolMed SpA, H1 2017

Gastric Cancer – Pipeline by NanoCarrier Co Ltd, H1 2017

Gastric Cancer – Pipeline by Novartis AG, H1 2017

Gastric Cancer – Pipeline by Novogen Ltd, H1 2017

Gastric Cancer – Pipeline by OBI Pharma Inc, H1 2017

Gastric Cancer – Pipeline by Oncobiologics Inc, H1 2017

Gastric Cancer – Pipeline by Oncolys BioPharma Inc, H1 2017

Gastric Cancer – Pipeline by OncoMed Pharmaceuticals Inc, H1 2017

Gastric Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Gastric Cancer – Pipeline by Opsona Therapeutics Ltd, H1 2017

Gastric Cancer – Pipeline by Panacea Biotec Ltd, H1 2017

Gastric Cancer – Pipeline by Patrys Ltd, H1 2017

Gastric Cancer – Pipeline by Pfizer Inc, H1 2017

Gastric Cancer – Pipeline by Pharma Mar SA, H1 2017

Gastric Cancer – Pipeline by Plexxikon Inc, H1 2017

Gastric Cancer – Pipeline by Puma Biotechnology Inc, H1 2017

Gastric Cancer – Pipeline by Redx Pharma Plc, H1 2017

Gastric Cancer – Pipeline by Rexahn Pharmaceuticals Inc, H1 2017

Gastric Cancer – Pipeline by Rgenix Inc, H1 2017

Gastric Cancer – Pipeline by Rhizen Pharmaceuticals SA, H1 2017

Gastric Cancer – Pipeline by Richter Gedeon Nyrt, H1 2017

Gastric Cancer – Pipeline by Samumed LLC, H1 2017

Gastric Cancer – Pipeline by Sanofi, H1 2017

Gastric Cancer – Pipeline by Selecta Biosciences Inc, H1 2017

Gastric Cancer – Pipeline by Sequella Inc, H1 2017

Gastric Cancer – Pipeline by Shionogi & Co Ltd, H1 2017

Gastric Cancer – Pipeline by Simcere Pharmaceutical Group, H1 2017

Gastric Cancer – Pipeline by Sorrento Therapeutics Inc, H1 2017

Gastric Cancer – Pipeline by Spectrum Pharmaceuticals Inc, H1 2017

Gastric Cancer – Pipeline by Stelic Institute & Co Inc, H1 2017

Gastric Cancer – Pipeline by Supratek Pharma Inc, H1 2017

Gastric Cancer – Pipeline by SynCore Biotechnology Co Ltd, H1 2017

Gastric Cancer – Pipeline by Synovo GmbH, H1 2017

Gastric Cancer – Pipeline by Synthon Holdings BV, H1 2017

Gastric Cancer – Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017

Gastric Cancer – Pipeline by Taiwan Liposome Company Ltd, H1 2017

Gastric Cancer – Pipeline by Takis Srl, H1 2017

Gastric Cancer – Pipeline by Tessa Therapeutics Pte Ltd, H1 2017

Gastric Cancer – Pipeline by Transgene SA, H1 2017

Gastric Cancer – Pipeline by United BioPharma Inc, H1 2017

Gastric Cancer – Pipeline by Vaxon Biotech, H1 2017

Gastric Cancer – Pipeline by Viracta Therapeutics Inc, H1 2017

Gastric Cancer – Pipeline by XuanZhu Pharma Co Ltd, H1 2017

Gastric Cancer – Pipeline by Zymeworks Inc, H1 2017

Gastric Cancer – Dormant Projects, H1 2017

Gastric Cancer – Dormant Projects, H1 2017 (Contd..1), H1 2017

Gastric Cancer – Dormant Projects, H1 2017 (Contd..2), H1 2017

Gastric Cancer – Dormant Projects, H1 2017 (Contd..3), H1 2017

Gastric Cancer – Dormant Projects, H1 2017 (Contd..4), H1 2017

Gastric Cancer – Dormant Projects, H1 2017 (Contd..5), H1 2017

Gastric Cancer – Dormant Projects, H1 2017 (Contd..6), H1 2017

Gastric Cancer – Dormant Projects, H1 2017 (Contd..7), H1 2017

Gastric Cancer – Discontinued Products, H1 2017

Gastric Cancer – Discontinued Products, H1 2017 (Contd..1), H1 2017

Gastric Cancer – Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures

List of Figures

Number of Products under Development for Gastric Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports